The Next Generation of Therapy for Multiple Myeloma: A Review of Ongoing Clinical Trials Utilizing Clinicaltrials.gov

Barth, Peter; Vale, Colin; Chambers, Alison; Reagan, John L.

doi:10.2217/fon-2017-0722

Cited by 5 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 We categorized the type of treatment as follows: chemotherapy, radiotherapy, surgery, combination therapy, immunotherapy (including PD-1, PD-L1, CTLA-4 blockade, CAR-T therapy, and vaccine therapy), and targeted therapy (defined as treatment that attacks specific features of cancer cells, excluding those whose main mechanism is through immune stimulation, such as PD-1, PD-L1, and CTLA-4 blockade). 14 , 15 An intervention that cannot fit into these classifications was classified as others.…”

Section: Methodsmentioning

confidence: 99%

The Current Landscape of Oral Squamous Cell Carcinoma: A Comprehensive Analysis from ClinicalTrials.gov

Zou

Wen

et al. 2022

Cancer Control

View full text Add to dashboard Cite

Objective A better understanding of the current characteristics of clinical trials in oral squamous cell carcinoma (OSCC) is important to improve trial design and identify neglected areas of research. The objective is to summarize the current characteristics and publication status of OSCC trials registered on ClinicalTrials.gov. Methods The ClinicalTrials.gov database was searched on November 9, 2020, for trials containing the term “oral squamous cell carcinoma”. We assessed the characteristics of the included trials and searched the publication status of the primary completed trials by using PubMed and Google Scholar. Results Our search identified 325 studies for analysis, including 279 interventional (85.8%) and 46 observational (14.2%) studies. Interventional studies were mostly single-group (50.9%), single-center (57.0%), non-randomized (59.1%), open-label (81.4%), and early-phase (70.6%) trials. The vast majority of the studies (82.8%) focused on the treatment of OSCC. Chemotherapy (36.8%) was the most common treatment, followed by targeted therapy (15.2%) and immunotherapy (15.2%). Furthermore, 58.9% of the primary completed interventional studies were published by January 8, 2021, and the median time to publication was 48.0 months. Studies registered before this study began (HR = 1.69, 95% CI = 1.02–2.80, P = .040) and in phases 1/2 or 2 (HR = 2.10, 95% CI = 1.09–4.06, P = .026) were associated with an improved likelihood of publication. Conclusions OSCC clinical trials usually have small sample size and are open-label and non-randomized studies. Advanced OSCC and immunotherapy-oriented therapy are becoming the focus of current trials. Researchers should perform standardized registration and publish their results in a timely manner.

show abstract

Section: Methodsmentioning

confidence: 99%